数据驱动的临床决策支持工具,用于诊断帕金森病中轻度认知障碍
Gabriel Martínez Tirado1, Patricia Martins Conde2, Stefano Sapienza2
1Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg. gabriel.martinez@uni.lu.
NPJ Parkinson's disease
|January 12, 2026
概括
机器学习 (ML) 模型可以帮助诊断帕金森病 (PD) 患者的轻度认知障碍 (MCI). 这些以数据为导向的方法显示了与临床试验相当的性能,并可以识别额外的MCI病例,改善日常护理中的诊断.
科学领域:
- 神经科学是一个神经科学.
- 医疗信息学 医疗信息学
- 计算生物学 计算生物学
背景情况:
- 帕金森病 (PD) 是一种神经退行性疾病,影响运动和认知功能.
- 轻度认知障碍 (MCI) 是PD患者痴呆症进展的重要危险因素.
- 目前的MCI诊断依赖于临床环境中的漫长,不切实际的神经心理评估.
研究的目的:
- 研究机器学习 (ML) 模型在帕金森病 (PwPD) 患者中诊断MCI的实用性.
- 将ML模型的性能与PD中MCI的确定的临床诊断标准进行比较.
- 探索ML的潜力,以识别传统方法错过的MCI病例.
主要方法:
- 来自卢森堡帕金森病研究的115名PwPD和226名健康对照的纵向数据的分析.
- 开发和应用数据驱动的ML模型,整合用于MCI诊断的临床数据.
- 将ML模型的性能与MDS PD-MCIII级临床参考测试进行比较.
主要成果:
- 基于ML的模型与MDS PD-MCIII级临床诊断测试相比,表现不劣.
- 通过ML模型,成功地确定了标准临床评估无法检测到的MCI个体的子组.
- 这突显了ML在帕金森病中增强MCI检测的潜力.
结论:
- 机器学习模型显示出作为帕金森病中MCI诊断的补充工具的希望.
- 在PwPD中,ML可以促进更早,更全面地检测认知障碍.
- 将ML纳入临床实践可能会改善帕金森病的诊断表征和管理.
更多相关视频
10:28Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
Published on: July 24, 2019
15.9K
07:26Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
Published on: September 26, 2019
8.2K
相关概念视频
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Parkinson's Disease: Treatment
970
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
970
Dementia
511
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
511
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
806
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
806
